Key Takeaways
- • American Industrial Partners (AIP) agreed to acquire Avanos Medical in an all-cash transaction valued at approximately $1.27 billion enterprise value, with shareholders receiving $25 per share in cash.
- • The acquisition represents a 72.1% premium to Avanos' last closing price, reflecting AIP's confidence in the medical device company's non-opioid pain management and nutrition product portfolios.
- • Avanos shareholders will benefit from immediate liquidity at a significant premium, with the deal expected to close in the second half of 2026.
- • AIP gains control of Coolief, Avanos' flagship minimally invasive radiofrequency ablation device for chronic pain treatment, positioning the company to compete in a crowded pain-management market against larger players including Stryker, Medtronic, and Boston Scientific.
- • The acquisition underscores private equity appetite for specialized medtech assets with established product-market fit in growing therapeutic areas focused on non-opioid alternatives and patient nutrition support.
Summary
American Industrial Partners announced on April 14, 2026, an agreement to acquire Avanos Medical in an all-cash transaction valued at approximately $1.27 billion in enterprise value. Under the terms of the agreement, Avanos shareholders will receive $25 per share in cash, representing a 72.1% premium to the stock's last closing price. The all-cash structure provides immediate certainty and liquidity for shareholders. The transaction is expected to close during the second half of 2026.
Avanos Medical, based in Alpharetta, Georgia, operates in two primary product segments: non-opioid chronic pain management and medical nutrition. The company manufactures medical devices including feeding tubes and related systems for patients unable to eat independently, as well as pain management solutions. The centerpiece of AIP's acquisition interest is Coolief, Avanos' flagship product—a minimally invasive radiofrequency ablation device that treats chronic pain by disabling pain-causing nerves without opioid administration. This device addresses a significant market need, particularly given ongoing regulatory and clinical scrutiny surrounding opioid pain management.
The acquisition reflects AIP's strategic bet on Avanos' positioned growth in non-opioid pain treatment and specialized medical nutrition markets. However, Coolief operates in a competitive landscape dominated by larger, diversified medtech players. Stryker, Medtronic, and Boston Scientific all offer competing ablation systems as part of broader product portfolios, which may present integration and competitive challenges for AIP. The private equity firm will need to execute a strategy that leverages Avanos' specialized focus while scaling operations to compete against substantially larger competitors with greater resources and market access.
The transaction demonstrates continued private equity appetite for established medtech assets with defensible product portfolios addressing underserved patient populations. AIP's acquisition aligns with broader industry trends favoring specialized medical device companies focused on non-opioid and minimally invasive therapeutic solutions.
Avanos Medical, based in Alpharetta, Georgia, operates in two primary product segments: non-opioid chronic pain management and medical nutrition. The company manufactures medical devices including feeding tubes and related systems for patients unable to eat independently, as well as pain management solutions. The centerpiece of AIP's acquisition interest is Coolief, Avanos' flagship product—a minimally invasive radiofrequency ablation device that treats chronic pain by disabling pain-causing nerves without opioid administration. This device addresses a significant market need, particularly given ongoing regulatory and clinical scrutiny surrounding opioid pain management.
The acquisition reflects AIP's strategic bet on Avanos' positioned growth in non-opioid pain treatment and specialized medical nutrition markets. However, Coolief operates in a competitive landscape dominated by larger, diversified medtech players. Stryker, Medtronic, and Boston Scientific all offer competing ablation systems as part of broader product portfolios, which may present integration and competitive challenges for AIP. The private equity firm will need to execute a strategy that leverages Avanos' specialized focus while scaling operations to compete against substantially larger competitors with greater resources and market access.
The transaction demonstrates continued private equity appetite for established medtech assets with defensible product portfolios addressing underserved patient populations. AIP's acquisition aligns with broader industry trends favoring specialized medical device companies focused on non-opioid and minimally invasive therapeutic solutions.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.